Скачать или смотреть LEQEMBI®: A New Hope for Alzheimer's Patients in Japan

Eisai and Biogen have submitted a new drug application for LEQEMBI® in Japan, offering a subcutaneous formulation for early Alzheimer's treatment. If approved, this at-home injection could revolutionize care. The application is based on successful sub-studies, showing equivalent exposure and benefits to IV administration. With a simple 15-second injection, LEQEMBI® could provide an alternative to hospital visits, expanding treatment options for patients and caregivers. This breakthrough treatment targets protofibrils and amyloid plaque, fighting Alzheimer's in two ways. LEQEMBI® is already approved in 51 countries and under review in 9 more. Learn more about this exciting development and its potential impact on Alzheimer's care.